<DOC>
	<DOCNO>NCT02157181</DOCNO>
	<brief_summary>The study test effectiveness ( rate complete remission , total remission rate duration remission ) toxicity combine immuno/chemotherapy subcutaneous cladribine ( LITAKÂ® ) plus anti-CD20* antibody rituximab patient require treatment relapse hairy cell leukaemia hairy cell leukaemia variant independent previous therapy . CD20* = cluster differentiation antigen 20</brief_summary>
	<brief_title>Treatment Hairy Cell Leukaemia Variant Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab</brief_title>
	<detailed_description>The trial prospective , multi-centre , open Phase II study patient hairy cell leukaemia variant relapse hairy cell leukaemia .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>2-chloro-3'-deoxyadenosine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<criteria>Patients histologically verify hairy cell leukaemia ( HCL ) Hairy cell leukaemia variant ( HCLv ) Relapse hairy cell leukaemia therapy cladribine pentostatin Need treatment indicate ( see 4.3 ) Age least 18 year General state health accord WHO 02 Written declaration consent patient Current histology , old 6 month , necessary Patients , fulfil abovementioned inclusion criterion . Patients severe functional limitation heart accord New York Heart Association III / IV , lung accord WHO degree III / IV , liver ( bilirubin &gt; 2mg/dl , alkaline phosphatase , raise GOT GPT ( glutamate pyruvate transaminase ) value twice normal ) , diseases central nervous system , include psychosis . Creatinine &gt; 2 mg/dl , creatinine clearance &lt; 50 mg/min Patients proven HIV infection Patients active hepatitis Patients florid infection Patients anamnesis / diagnosis another malignant disease ( nonmelanoma associate skin tumour stage 0 situ carcinoma cervix ) Pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>HCL variant</keyword>
	<keyword>HCL relapse</keyword>
	<keyword>Risk stratify</keyword>
</DOC>